Compare CCEP & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCEP | HLN |
|---|---|---|
| Founded | 1986 | 2022 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Package Goods/Cosmetics |
| Sector | Consumer Staples | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4B | 43.7B |
| IPO Year | 2015 | N/A |
| Metric | CCEP | HLN |
|---|---|---|
| Price | $104.52 | $11.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $106.67 | N/A |
| AVG Volume (30 Days) | 1.6M | ★ 7.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.23% | 1.63% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.93 | $1.62 |
| Revenue Next Year | $3.93 | $4.39 |
| P/E Ratio | ★ $20.93 | $49.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $80.70 | $8.71 |
| 52 Week High | $106.05 | $11.42 |
| Indicator | CCEP | HLN |
|---|---|---|
| Relative Strength Index (RSI) | 83.14 | 66.97 |
| Support Level | $95.26 | $11.11 |
| Resistance Level | $97.72 | $11.28 |
| Average True Range (ATR) | 2.11 | 0.15 |
| MACD | 1.09 | 0.02 |
| Stochastic Oscillator | 89.73 | 80.50 |
CCEP is the second-largest bottling partner in the Coca-Cola system by volume, behind Coca-Cola Femsa, and primarily operates in developed Europe, Australasia, and Southeast Asia.In 2024, CCEP sold 3.9 billion unit cases of beverages, which we estimate equates to roughly 9% of the global Coke system volume. Coke's largest bottler, Coca-Cola Femsa, sold over 4 billion unit cases (12%), and the third-largest, Coca-Cola HBC, serving Eastern Europe and North Africa, sold 2.8 billion unit cases (8%).TCCC owns 19% of the equity of CCEP, Olive Partners, a holding company of bottling operations, owns a further 36%, and the remaining 45% is free float.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.